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Supplementary 1 Distribution of sucrose in the sucrose density gradient. The amount 1 
of sucrose in each fraction post centrifugation was analysed. Fraction 1 contained 12.45%, 2 
fraction 2 24.6% and fraction 3 26.51% of sucrose, with a standard deviation of 2.7, 2.4 and 3 
1.5 respectively.  4 
 5 
Supplementary 2 Standard curves used to quantify lipid concentrations by HPTLC and 6 
TLC. Standard curves were produced for 10 different lipids by loading increasing 7 
concentrations onto HPTLC plates and for Gb3 TLC plates: Phosphatidylcholine (PC), 8 
phosphoethanolamine (PE), galactocerebroside (GC), sphingomyelin (SM), 9 
monoacylglycerol (MG), free fatty acids (FFA), cholesterol ester (CE), phosphatidylserine 10 
(PS), cardiolipin (CA), Globotriaosylceramide (Gb3). The lowest detection limits and linear 11 
ranges were also determined for each lipid. A standard curve used to quantify the lipid 12 
concentration of each sample was generated by using at least 5 different values within the 13 
linear range. Band intensities acquired for each lipid were only used when they above the 14 
minimum detection limit and within the linear range of the corresponding lipid standard.  15 
 16 
Supplementary 3 Flotillin-2 distribution from two different wild type fibroblasts. 17 
Flotillin-2 distribution (in percentage) from two different wild type fibroblasts showing a higher 18 
concentration of the lipid raft-associated protein in fractions 1 and 2. Flotillin 2 distribution for 19 
the shown immunoblots are for WT 1; 39.3%, 37.2% and 6.8%, and for WT 2; 28.5%, 43.5% 20 
and 7.6% for sucrose fractions 1, 2 and 3 respectively. WT 2, which is closer to the FD 21 
fibroblasts, was used in all experiments presented throughout this study as WT. 22 
 23 
Supplementary 4 Effect of NB-DNJ on the flotillin-2 distribution in sucrose density 24 
gradient fractions isolated from fibroblasts derived from Fabry patients 25 
Fibroblasts derived from a Fabry patient (N215S) or age-matched healthy individuals (WT) 26 
were treated with NB-DNJ for three days and were subsequently lysed with 1% (w/v) Triton 27 
X-100 and run on density-based sucrose gradients. Ten fractions were collected and 28 
analysed for distribution of flotillin-2 by immunoblotting. The results are displayed as a 29 
percentage of the total flotillin-2 detected throughout all 10 fractions. (*p<0.05, ±SD, n=3). 30 
 31 
Supplementary 5 Table showing the flotillin-2 distribution in sucrose density gradient 32 
fractions isolated from fibroblasts derived from Fabry patients post NB-DNJ treatment 33 
Fibroblasts derived from a Fabry patient (N215S) or age-matched healthy individuals (WT) 34 
were treated with NB-DNJ for three days and were subsequently lysed with 1% (w/v) Triton 35 
X-100 and run on density-based sucrose gradients. Ten fractions were collected and 36 
analysed for distribution of flotillin-2 by immunoblotting. The results are displayed as a 37 
percentage of the total flotillin-2 detected throughout all 10 fractions. (*p<0.05, SEM, n=3).  38 
 39 
Supplementary 6 Cholesterol distribution in sucrose density gradient fractions 40 
Fibroblasts derived from a Fabry patient (N215S) or age-matched healthy individuals (WT) 41 
were treated with NB-DNJ for three days and were subsequently lysed with 1% (w/v) Triton 42 
X-100 and run on density-based sucrose gradients. Ten fractions were collected and the 43 
cholesterol content was analysed via HPLC. The results are expressed as a percentage of 44 
the total cholesterol quantified from the 6 samples analysed, fractions 1, 2, 3 and 8, 9 and 45 
10, which contained cholesterol at concentrations above the minimum detection limit. 46 
(*p<0.05, SEM, n=3). 47 
 48 
Supplementary 7 Table showing the cholesterol distribution in sucrose density 49 
gradient fractions 50 
Fibroblasts derived from a Fabry patient (N215S) or age-matched healthy individuals (WT) 51 
were treated with NB-DNJ for three days and were subsequently lysed with 1% (w/v) Triton 52 
X-100 and run on density-based sucrose gradients. Ten fractions were collected and the 53 
cholesterol content was analysed via HPLC. The results are expressed as a percentage of 54 
the total cholesterol quantified from the 6 samples analysed, fractions 1, 2, 3 and 8, 9 and 55 
10, which contained cholesterol at concentrations above the minimum detection limit. 56 
(*p<0.05, ±SD, n=3). 57 
 58 
Supplementary 8 Fibroblasts derived from a Fabry patient (N215S) or age-matched healthy 59 
individuals (WT) were lysed with 1% (w/v) Triton X-100 and run on density-based sucrose 60 
gradient. Nine fractions were collected and analysed for distribution of the lipid raft-61 
associated flotillin-2 by immunoblotting. Flotillin-2 distribution was calculated by grouping the 62 
lipid raft fractions 1-3 and non-raft fraction 8-10 and shown as a percentage. No significant 63 
difference was found in the raft and non-raft flotillin-2 distributions between wild type and 64 
Fabry fibroblasts.  65 
 66 
Supplementary 9 DPPIV trafficking to the cell surface is impaired in Fabry fibroblasts. 67 
Fibroblasts were solubilised in standard lysis buffer. Intra- and extracellular distribution 68 
analysis of the lipid raft associated DPPIV protein was performed using biotinylation and 69 
Western blotting of the obtained isolate. The results show that the cell surface consists 70 
almost entirely of the complex glycosylated form of DPPIV (DPPIVc) in both the wild type and 71 
Fabry fibroblasts (A). The intracellularly located DPPIV was present in both complex (upper 72 
band) and high mannose (lower band) forms. Lower band intensities of both the DPPIVc and 73 
DPPIVh forms of the protein were present in Fabry fibroblasts relative to the wild type 74 
fibroblasts. Fabry fibroblasts have lower concentrations of DPPIV on the cell surface 75 
compared to wild type cells (B). 76 
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